We are live on ! Find out more
5VM

5AM Venture Management Portfolio holdings

AUM $360M
1-Year Est. Return 345.76%
This Fund
S&P 500
This Quarter Est. Return
-24.01%
1 Year Est. Return
+345.76%
3 Year Est. Return
+491.51%
5 Year Est. Return
+330.26%
10 Year Est. Return
–
AUM
$397M
AUM Growth
-$158M
Cap. Flow
+$34.3M
Cap. Flow %
8.63%
Top 10 Hldgs %
98.06%
Holding
13
New
2
Increased
–
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
IMPL
Impel Pharmaceuticals Inc. Common Stock
IMPL
+$34.4M
2
JANX icon
Janux Therapeutics
JANX
+$9.94M

Top Sells

Rank Stock Value
1
ARVN icon
Arvinas
ARVN
+$6.94M
2
APRE icon
Aprea Therapeutics
APRE
+$3.16M

Sector Composition

Rank Sector Weight
1 Healthcare 99.08%
2 Financials 0.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VOR icon
1
Vor Biopharma
VOR
$1.16B
$125M 31.41%
334,621
– –
AKUS
2
DELISTED
Akouos Inc
AKUS
$51.9M 13.06%
4,135,784
– –
IDYA icon
3
IDEAYA Biosciences
IDYA
$3.41B
$37.7M 9.5%
1,798,066
– –
QTTB icon
4
Q32 Bio
QTTB
$450M
$33M 8.3%
251,996
– –
ARVN icon
5
Arvinas
ARVN
$520M
$30.8M 7.75%
400,000
-100,000
-20% -$6.94M
CRNX icon
6
Crinetics Pharmaceuticals
CRNX
$8.89B
$25.7M 6.46%
1,362,286
– –
CABA icon
7
Cabaletta Bio
CABA
$439M
$25.7M 6.46%
2,984,263
– –
IMPL
8
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
$25.5M 6.43%
+2,884,791
New +$34.4M
SCPH
9
DELISTED
scPharmaceuticals
SCPH
$23.4M 5.89%
3,831,474
– –
JANX icon
10
Janux Therapeutics
JANX
$934M
$11.1M 2.8%
+446,266
New +$9.94M
CDTX
11
DELISTED
Cidara Therapeutics
CDTX
$4.05M 1.02%
100,326
– –
FVAM
12
DELISTED
5:01 Acquisition Corp
FVAM
$3.64M 0.92%
365,126
– –
APRE icon
13
Aprea Therapeutics
APRE
$7.4M
– –
-30,958
Closed -$3.16M

Similar funds

LSC
Logan Stone Capital Chicago, Illinois $360M AUM 9.71% 1-Year Est. Return
WIP
WealthCare Investment Partners Portsmouth, Rhode Island $360M AUM 19.98% 1-Year Est. Return
RA
RR Advisors Dallas, Texas $360M AUM 28.52% 1-Year Est. Return
SWM
SK Wealth Management Providence, Rhode Island $360M AUM 14.81% 1-Year Est. Return
NC
Naman Capital Sao Paulo, Brazil $360M AUM 27.43% 1-Year Est. Return
MCM
Monimus Capital Management Woodbridge, New Jersey $361M AUM 21.17% 1-Year Est. Return
KLWA
Kelly Lawrence W & Associates Pasadens, California $360M AUM 16.9% 1-Year Est. Return
PWC
PYA Waltman Capital Knoxville, Tennessee $361M AUM 9.49% 1-Year Est. Return

5AM Venture Management's Q2 2021 Portfolio in Review

As of Q2 2021, 5AM Venture Management held 13 positions worth $397M, down 28% from $555M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

5AM Venture Management deployed $34.3M of net new capital in Q2 2021, opening 2 new positions. Its largest new stake was Impel Pharmaceuticals Inc. Common Stock: 2,884,791 shares worth $25.5M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Arvinas, an estimated $6.94M trimmed.

  • 5AM Venture Management's largest Q2 2021 buy was Impel Pharmaceuticals Inc. Common Stock: 2,884,791 shares worth $25.5M.
  • 5AM Venture Management's biggest Q2 2021 reduction was Arvinas, cutting an estimated $6.94M.
  • 5AM Venture Management fully exited Aprea Therapeutics in Q2 2021, selling an estimated $3.16M.
  • 5AM Venture Management's ten largest holdings make up 98% of its $397M portfolio in Q2 2021.
  • 5AM Venture Management opened 2 new positions and closed 1 in Q2 2021.
  • 5AM Venture Management's portfolio value fell 28% quarter-over-quarter to $397M.

Based on 5AM Venture Management's 13F filing for Q2 2021, filed 16 Aug 2021.